132 related articles for article (PubMed ID: 16114015)
1. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
Zaman K; Driscoll R; Hahn D; Werffeli P; Goodman SL; Bauer J; Leyvraz S; Lejeune F; Stupp R; Rüegg C
Int J Cancer; 2006 Feb; 118(3):755-64. PubMed ID: 16114015
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and diagnostic implications of MMP-2, MMP-9, and VEGF-α expressions in colorectal cancer.
Araújo RF; Lira GA; Vilaça JA; Guedes HG; Leitão MC; Lucena HF; Ramos CC
Pathol Res Pract; 2015 Jan; 211(1):71-7. PubMed ID: 25446246
[TBL] [Abstract][Full Text] [Related]
3. BLCA-4 expression is related to MMP-9, VEGF, IL-1α and IL-8 in bladder cancer but not to PEDF, TNF-α or angiogenesis.
Feng C; Wu Z; Guo T; Jiang H; Guan M; Zhang Y; Wen H; Ding Q
Pathol Biol (Paris); 2012 Jun; 60(3):e36-40. PubMed ID: 22197408
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence.
Chin KF; Greenman J; Reusch P; Gardiner E; Marme D; Monson JR
Eur J Surg Oncol; 2003 Aug; 29(6):497-505. PubMed ID: 12875855
[TBL] [Abstract][Full Text] [Related]
5. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array.
Abajo A; Bitarte N; Zarate R; Boni V; Lopez I; Gonzalez-Huarriz M; Rodriguez J; Bandres E; Garcia-Foncillas J
World J Gastroenterol; 2012 Feb; 18(7):637-45. PubMed ID: 22363134
[TBL] [Abstract][Full Text] [Related]
6. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
7. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.
Hawinkels LJ; Zuidwijk K; Verspaget HW; de Jonge-Muller ES; van Duijn W; Ferreira V; Fontijn RD; David G; Hommes DW; Lamers CB; Sier CF
Eur J Cancer; 2008 Sep; 44(13):1904-13. PubMed ID: 18691882
[TBL] [Abstract][Full Text] [Related]
8. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
[TBL] [Abstract][Full Text] [Related]
9. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
[TBL] [Abstract][Full Text] [Related]
10. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.
Marien KM; Croons V; Martinet W; De Loof H; Ung C; Waelput W; Scherer SJ; Kockx MM; De Meyer GR
Expert Rev Mol Diagn; 2015 Mar; 15(3):399-414. PubMed ID: 25585649
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas.
Munaut C; Noël A; Hougrand O; Foidart JM; Boniver J; Deprez M
Int J Cancer; 2003 Oct; 106(6):848-55. PubMed ID: 12918061
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
[TBL] [Abstract][Full Text] [Related]
13. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
[TBL] [Abstract][Full Text] [Related]
14. Plasma VEGF-A and its soluble receptor R1 correlate with the clinical stage of colorectal cancer.
Myśliwiec P; Piotrowski Z; Zalewski B; Kukliński A; Pawlak K
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():85-7. PubMed ID: 15638384
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis.
Yang Q; Ye ZY; Zhang JX; Tao HQ; Li SG; Zhao ZS
Anat Rec (Hoboken); 2010 Dec; 293(12):2012-9. PubMed ID: 21089052
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course.
Tang JH; Zhao JH; Lu JW; Yan F; Qin JW; Xu B
J Cancer Res Clin Oncol; 2011 Jan; 137(1):55-63. PubMed ID: 20221635
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections.
Chin KF; Greenman J; Reusch P; Gardiner E; Marme D; Monson J
Anticancer Res; 2004; 24(4):2353-7. PubMed ID: 15330184
[TBL] [Abstract][Full Text] [Related]
18. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Ferretti G; Fabi A; Carlini P; Papaldo P; Cordiali Fei P; Di Cosimo S; Salesi N; Giannarelli D; Alimonti A; Di Cocco B; D'Agosto G; Bordignon V; Trento E; Cognetti F
Oncology; 2005; 69(1):35-43. PubMed ID: 16088233
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
